Global Radiation Dermatitis Market

Radiation Dermatitis Comprehensive Study by Type (Grade 1, Grade 2, Grade 3, Grade 4), Application (Hospitals, Pharmaceuticals, Clinics, Others), Drug Administration (Oral, Topical, Dressing, Other) Players and Region - Global Market Outlook to 2029

Radiation Dermatitis Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Radiation Dermatitis Market Overview:
Radiation Dermatitis is one of the side effects of radiotherapy in the treatment of cancer. Radiation Dermatitis occurs in more than 95% of people who undergo radiation dermatitis. It occurs when radiation therapy damages the outer layer of people’s skin. When hospitals or doctors use X-rays, gamma rays to destroy cancer cells; these rays also make tiny breaks in DNA inside tiny cells to stop it from growing and dividing but this also leads to exposure of these rays to normal rays that get damaged. Radiation Dermatitis has different severity with respect to people. Some individuals experience mild redness while others may experience painful and broken skin. The symptoms of Radiation Dermatitis typically arise after a few weeks or days. Which may include redness or pinkiness of skin, skin swelling, peeling skin, blisters, or skin ulcers. As, radiotherapy is one of the most effective and common methods to treat cancer the radiation dermatitis is very common.

AttributesDetails
Study Period2019-2029
Base Year2023
Forecast Period2022-2029
Historical Period2019-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increasing Demand for Alcohol-Free Moisturizer for Applying on Affected Skin

Market Growth Drivers:
Growing Prevalence of Cancer Disease and Side Effects Related to the Treatment and Need of Radiology for The Treatment of Cancer Which Causes Radiation Dermatitis

Challenges:
High Cost Associated with Treating Severe Radiation Dermatitis.

Restraints:
Lack of Medical Infrastructure in Developing Countries

Opportunities:
Availability of Medical Infrastructure in Developed Countries and Increasing Spendings of People on the Diagosis

Competitive Landscape:
With the increasing use of radiotherapy as a treatment for cancer, the demand for radiation dermatitis medication is increasing. The market is fragmented and does not any distinct market leader. There are no major barriers to entry into the market for new entrants but gaining a good reputation could be a challenge. Radiation Dermatitis is good to segment to expand into if some company is already operating in the skincare market.
Some of the key players profiled in the report are 3M Health Care (United States), Charles River Laboratories (United States), Sonoma Pharmaceuticals (United States), ICON PLC. (Ireland), Eurofins Scientific (Luxembourg), Taconic Biosciences (United States), Mölnlycke Health Care AB (Sweden), Smith & Nephew plc (United Kingdom) and EVOTEC (United Kingdom). Additionally, following companies can also be profiled that are part of our coverage like Integra Lifesciences Holdings Corporation (United States) and Intermed S.A. (Greece). Analyst at AMA Research see United States Players to retain maximum share of Global Radiation Dermatitis market by 2029. Considering Market by Drug Administration, the sub-segment i.e. Oral will boost the Radiation Dermatitis market.

Latest Market Insights:
In Feb. , 2020 Sonoma Pharmaceuticals, Inc. a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin and wound conditions, is pleased to announce that it successfully closed on an asset purchase agreement for certain wound care,

Dec 10, 2020, Sonoma Pharmaceuticals a healthcare leader who also manufactures medication for Radiation Dermatitis and Crown Laboratories, a global skincare company announced that they have entered into a supply agreement for the exclusive rights to sell and market products for the over-the-counter dermatological market in the United States. Both Companies plan to sell a unique variety of formulations to quickly relieve itch and skin irritations.

What Can be Explored with the Radiation Dermatitis Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Radiation Dermatitis Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Radiation Dermatitis
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Radiation Dermatitis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Radiation Dermatitis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Radiation Dermatitis Medication Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Grade 1
  • Grade 2
  • Grade 3
  • Grade 4
By Application
  • Hospitals
  • Pharmaceuticals
  • Clinics
  • Others
By Drug Administration
  • Oral
  • Topical
  • Dressing
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Cancer Disease and Side Effects Related to the Treatment
      • 3.2.2. Need of Radiology for The Treatment of Cancer Which Causes Radiation Dermatitis
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated with Treating Severe Radiation Dermatitis.
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand for Alcohol-Free Moisturizer for Applying on Affected Skin
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radiation Dermatitis, by Type, Application, Drug Administration and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Radiation Dermatitis (Value)
      • 5.2.1. Global Radiation Dermatitis by: Type (Value)
        • 5.2.1.1. Grade 1
        • 5.2.1.2. Grade 2
        • 5.2.1.3. Grade 3
        • 5.2.1.4. Grade 4
      • 5.2.2. Global Radiation Dermatitis by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Pharmaceuticals
        • 5.2.2.3. Clinics
        • 5.2.2.4. Others
      • 5.2.3. Global Radiation Dermatitis by: Drug Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Topical
        • 5.2.3.3. Dressing
        • 5.2.3.4. Other
      • 5.2.4. Global Radiation Dermatitis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Radiation Dermatitis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 3M Health Care (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Charles River Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sonoma Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ICON PLC. (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eurofins Scientific (Luxembourg)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Taconic Biosciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mölnlycke Health Care AB (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Smith & Nephew plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. EVOTEC (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Radiation Dermatitis Sale, by Type, Application, Drug Administration and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Radiation Dermatitis (Value)
      • 7.2.1. Global Radiation Dermatitis by: Type (Value)
        • 7.2.1.1. Grade 1
        • 7.2.1.2. Grade 2
        • 7.2.1.3. Grade 3
        • 7.2.1.4. Grade 4
      • 7.2.2. Global Radiation Dermatitis by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Pharmaceuticals
        • 7.2.2.3. Clinics
        • 7.2.2.4. Others
      • 7.2.3. Global Radiation Dermatitis by: Drug Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Topical
        • 7.2.3.3. Dressing
        • 7.2.3.4. Other
      • 7.2.4. Global Radiation Dermatitis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radiation Dermatitis: by Type(USD Million)
  • Table 2. Radiation Dermatitis Grade 1 , by Region USD Million (2018-2023)
  • Table 3. Radiation Dermatitis Grade 2 , by Region USD Million (2018-2023)
  • Table 4. Radiation Dermatitis Grade 3 , by Region USD Million (2018-2023)
  • Table 5. Radiation Dermatitis Grade 4 , by Region USD Million (2018-2023)
  • Table 6. Radiation Dermatitis: by Application(USD Million)
  • Table 7. Radiation Dermatitis Hospitals , by Region USD Million (2018-2023)
  • Table 8. Radiation Dermatitis Pharmaceuticals , by Region USD Million (2018-2023)
  • Table 9. Radiation Dermatitis Clinics , by Region USD Million (2018-2023)
  • Table 10. Radiation Dermatitis Others , by Region USD Million (2018-2023)
  • Table 11. Radiation Dermatitis: by Drug Administration(USD Million)
  • Table 12. Radiation Dermatitis Oral , by Region USD Million (2018-2023)
  • Table 13. Radiation Dermatitis Topical , by Region USD Million (2018-2023)
  • Table 14. Radiation Dermatitis Dressing , by Region USD Million (2018-2023)
  • Table 15. Radiation Dermatitis Other , by Region USD Million (2018-2023)
  • Table 16. South America Radiation Dermatitis, by Country USD Million (2018-2023)
  • Table 17. South America Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 18. South America Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 19. South America Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 20. Brazil Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 21. Brazil Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 22. Brazil Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 23. Argentina Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 24. Argentina Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 25. Argentina Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 26. Rest of South America Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 29. Asia Pacific Radiation Dermatitis, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 33. China Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 34. China Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 35. China Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 36. Japan Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 37. Japan Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 38. Japan Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 39. India Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 40. India Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 41. India Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 42. South Korea Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 43. South Korea Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 44. South Korea Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 45. Taiwan Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 46. Taiwan Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 47. Taiwan Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 48. Australia Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 49. Australia Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 50. Australia Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 54. Europe Radiation Dermatitis, by Country USD Million (2018-2023)
  • Table 55. Europe Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 56. Europe Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 57. Europe Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 58. Germany Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 59. Germany Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 60. Germany Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 61. France Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 62. France Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 63. France Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 64. Italy Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 65. Italy Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 66. Italy Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 67. United Kingdom Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 69. United Kingdom Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 70. Netherlands Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 71. Netherlands Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 72. Netherlands Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 73. Rest of Europe Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 75. Rest of Europe Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 76. MEA Radiation Dermatitis, by Country USD Million (2018-2023)
  • Table 77. MEA Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 78. MEA Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 79. MEA Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 80. Middle East Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 81. Middle East Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 82. Middle East Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 83. Africa Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 84. Africa Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 85. Africa Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 86. North America Radiation Dermatitis, by Country USD Million (2018-2023)
  • Table 87. North America Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 88. North America Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 89. North America Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 90. United States Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 91. United States Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 92. United States Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 93. Canada Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 94. Canada Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 95. Canada Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 96. Mexico Radiation Dermatitis, by Type USD Million (2018-2023)
  • Table 97. Mexico Radiation Dermatitis, by Application USD Million (2018-2023)
  • Table 98. Mexico Radiation Dermatitis, by Drug Administration USD Million (2018-2023)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Radiation Dermatitis: by Type(USD Million)
  • Table 109. Radiation Dermatitis Grade 1 , by Region USD Million (2024-2029)
  • Table 110. Radiation Dermatitis Grade 2 , by Region USD Million (2024-2029)
  • Table 111. Radiation Dermatitis Grade 3 , by Region USD Million (2024-2029)
  • Table 112. Radiation Dermatitis Grade 4 , by Region USD Million (2024-2029)
  • Table 113. Radiation Dermatitis: by Application(USD Million)
  • Table 114. Radiation Dermatitis Hospitals , by Region USD Million (2024-2029)
  • Table 115. Radiation Dermatitis Pharmaceuticals , by Region USD Million (2024-2029)
  • Table 116. Radiation Dermatitis Clinics , by Region USD Million (2024-2029)
  • Table 117. Radiation Dermatitis Others , by Region USD Million (2024-2029)
  • Table 118. Radiation Dermatitis: by Drug Administration(USD Million)
  • Table 119. Radiation Dermatitis Oral , by Region USD Million (2024-2029)
  • Table 120. Radiation Dermatitis Topical , by Region USD Million (2024-2029)
  • Table 121. Radiation Dermatitis Dressing , by Region USD Million (2024-2029)
  • Table 122. Radiation Dermatitis Other , by Region USD Million (2024-2029)
  • Table 123. South America Radiation Dermatitis, by Country USD Million (2024-2029)
  • Table 124. South America Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 125. South America Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 126. South America Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 127. Brazil Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 128. Brazil Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 129. Brazil Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 130. Argentina Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 131. Argentina Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 132. Argentina Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 133. Rest of South America Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 134. Rest of South America Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 135. Rest of South America Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 136. Asia Pacific Radiation Dermatitis, by Country USD Million (2024-2029)
  • Table 137. Asia Pacific Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 138. Asia Pacific Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 139. Asia Pacific Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 140. China Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 141. China Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 142. China Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 143. Japan Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 144. Japan Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 145. Japan Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 146. India Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 147. India Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 148. India Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 149. South Korea Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 150. South Korea Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 151. South Korea Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 152. Taiwan Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 153. Taiwan Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 154. Taiwan Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 155. Australia Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 156. Australia Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 157. Australia Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 158. Rest of Asia-Pacific Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 159. Rest of Asia-Pacific Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 160. Rest of Asia-Pacific Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 161. Europe Radiation Dermatitis, by Country USD Million (2024-2029)
  • Table 162. Europe Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 163. Europe Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 164. Europe Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 165. Germany Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 166. Germany Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 167. Germany Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 168. France Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 169. France Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 170. France Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 171. Italy Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 172. Italy Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 173. Italy Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 174. United Kingdom Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 175. United Kingdom Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 176. United Kingdom Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 177. Netherlands Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 178. Netherlands Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 179. Netherlands Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 180. Rest of Europe Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 181. Rest of Europe Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 182. Rest of Europe Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 183. MEA Radiation Dermatitis, by Country USD Million (2024-2029)
  • Table 184. MEA Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 185. MEA Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 186. MEA Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 187. Middle East Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 188. Middle East Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 189. Middle East Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 190. Africa Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 191. Africa Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 192. Africa Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 193. North America Radiation Dermatitis, by Country USD Million (2024-2029)
  • Table 194. North America Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 195. North America Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 196. North America Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 197. United States Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 198. United States Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 199. United States Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 200. Canada Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 201. Canada Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 202. Canada Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 203. Mexico Radiation Dermatitis, by Type USD Million (2024-2029)
  • Table 204. Mexico Radiation Dermatitis, by Application USD Million (2024-2029)
  • Table 205. Mexico Radiation Dermatitis, by Drug Administration USD Million (2024-2029)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radiation Dermatitis: by Type USD Million (2018-2023)
  • Figure 5. Global Radiation Dermatitis: by Application USD Million (2018-2023)
  • Figure 6. Global Radiation Dermatitis: by Drug Administration USD Million (2018-2023)
  • Figure 7. South America Radiation Dermatitis Share (%), by Country
  • Figure 8. Asia Pacific Radiation Dermatitis Share (%), by Country
  • Figure 9. Europe Radiation Dermatitis Share (%), by Country
  • Figure 10. MEA Radiation Dermatitis Share (%), by Country
  • Figure 11. North America Radiation Dermatitis Share (%), by Country
  • Figure 12. Global Radiation Dermatitis share by Players 2023 (%)
  • Figure 13. Global Radiation Dermatitis share by Players (Top 3) 2023(%)
  • Figure 14. Global Radiation Dermatitis share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. 3M Health Care (United States) Revenue, Net Income and Gross profit
  • Figure 17. 3M Health Care (United States) Revenue: by Geography 2023
  • Figure 18. Charles River Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Charles River Laboratories (United States) Revenue: by Geography 2023
  • Figure 20. Sonoma Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 21. Sonoma Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 22. ICON PLC. (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. ICON PLC. (Ireland) Revenue: by Geography 2023
  • Figure 24. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 25. Eurofins Scientific (Luxembourg) Revenue: by Geography 2023
  • Figure 26. Taconic Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 27. Taconic Biosciences (United States) Revenue: by Geography 2023
  • Figure 28. Mölnlycke Health Care AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 29. Mölnlycke Health Care AB (Sweden) Revenue: by Geography 2023
  • Figure 30. Smith & Nephew plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Smith & Nephew plc (United Kingdom) Revenue: by Geography 2023
  • Figure 32. EVOTEC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. EVOTEC (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Global Radiation Dermatitis: by Type USD Million (2024-2029)
  • Figure 35. Global Radiation Dermatitis: by Application USD Million (2024-2029)
  • Figure 36. Global Radiation Dermatitis: by Drug Administration USD Million (2024-2029)
  • Figure 37. South America Radiation Dermatitis Share (%), by Country
  • Figure 38. Asia Pacific Radiation Dermatitis Share (%), by Country
  • Figure 39. Europe Radiation Dermatitis Share (%), by Country
  • Figure 40. MEA Radiation Dermatitis Share (%), by Country
  • Figure 41. North America Radiation Dermatitis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • 3M Health Care (United States)
  • Charles River Laboratories (United States)
  • Sonoma Pharmaceuticals (United States)
  • ICON PLC. (Ireland)
  • Eurofins Scientific (Luxembourg)
  • Taconic Biosciences (United States)
  • Mölnlycke Health Care AB (Sweden)
  • Smith & Nephew plc (United Kingdom)
  • EVOTEC (United Kingdom)
Additional players considered in the study are as follows:
Integra Lifesciences Holdings Corporation (United States) , Intermed S.A. (Greece)
Select User Access Type

Key Highlights of Report


Jan 2024 208 Pages 89 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Radiation Dermatitis Market Quantitative research analysis
Global Radiation Dermatitis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Radiation Dermatitis market are 3M Health Care (United States), Charles River Laboratories (United States), Sonoma Pharmaceuticals (United States), ICON PLC. (Ireland), Eurofins Scientific (Luxembourg), Taconic Biosciences (United States), Mölnlycke Health Care AB (Sweden), Smith & Nephew plc (United Kingdom) and EVOTEC (United Kingdom), to name a few.
"Increasing Demand for Alcohol-Free Moisturizer for Applying on Affected Skin" is seen as one of major influencing trends for Radiation Dermatitis Market during projected period 2023-2029.
Grade 1 segment in Global market to hold robust market share owing to "Growing Prevalence of Cancer Disease and Side Effects Related to the Treatment ".

Know More About Global Radiation Dermatitis Market Report?

Have a Query? Click Here

Other Related Reports

Acute Agitation and Aggression Treatment Comprehensive Study by Therapy (Chemotherapy, Cognitive Behavioural Therapy (CBT), Others), Route of Administration (Oral, Sublingual, Intramuscular, Others),...
$ 3750
Dyslexia Treatment Comprehensive Study by Type (Phonological Dyslexia, Surface Dyslexia), Treatment (Drug Class, Tools, Educational Techniques), End-users (Hospitals, Home Care, Others), Distribution...
$ 3450
Deep Vein Thrombosis Treatment Comprehensive Study by Type (Medication, Devices, Surgery), Application (Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis, Other), End Users (Hospitals, Ho...
$ 3750
Veterinary Artificial Insemination Comprehensive Study by Type (Equipment (Semen Applicator, Insemination Gun, Others), Consumables (Sheath, Lubricant, Glove, Heat Detector, Others), Accessories), An...
$ 3650
Dent Disease Treatment Comprehensive Study by Drug Type (Calcium Phosphate, Cysteine, Angiotensin-Converting Enzyme (ACE) Inhibitor, Angiotensin Receptor Blockers, Uric Acid, Calcium Oxalate, Thiazid...
$ 3750
Rhinoplasty Comprehensive Study by Type (Closed Rhinoplasty hidden inside the nose., Open Rhinoplasty, Filler Rhinoplasty, Revision Rhinoplasty), Application (Power setting of the console,, Density o...
$ 3450